Why the study?
Does ifosfamide-based chemotherapy improve disease-specific survival in adult patients with high-risk, primary, extremity, synovial sarcoma?
Does ifosfamide-based chemotherapy improve disease-specific survival in adult patients with high-risk, primary, extremity, synovial sarcoma?
Ifosfamide-based chemotherapy is associated with improved disease-specific survival in adult patients with high-risk primary extremity synovial sarcoma.
May support ifosfamide consideration in high-risk cases; leaves open randomized confirmation of survival benefit.
Ifosfamide-based chemotherapy was associated with an improved DSS in adult patients with high-risk, primary, extremity, synovial sarcoma and should be considered in the treatment of such patients.
No takes yet. Share an insight, caveat, or question.
Eilber et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: